person · Reporting owner

Parker Geoffrey M.

Disclosed activity across 7 companies

Tapewire entity: 37676
SEC CIK: 0001491874

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allogene Therapeutics, Inc.ALLO · Entity 5243	CHIEF FINANCIAL OFFICER	February 02, 2026	February 04, 2026
Better Therapeutics, Inc.BTTX · Entity 94385	Director	December 18, 2023	December 20, 2023
PERRIGO Co plcPRGO · Entity 4516	Director	September 11, 2026	September 15, 2026
Tricida, Inc.TCDA · Entity 122050	COO, CFO and EVP	February 28, 2022	March 02, 2022
Viracta Therapeutics, Inc.SNSS · Entity 85616	Director	May 31, 2017	June 02, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allogene Therapeutics, Inc.

Report date February 02, 2026 · Filed February 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,252,795	Reported balance After 2026-02-02 transaction · row 1 1 source row Row 1 · 2026-02-02 · Sale · Disposed 24,001 · Balance 1,252,795 F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2036-02-02	Direct	539,072	Reported balance After 2026-02-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-02 · Grant · Acquired 539,072 · Balance 539,072 F3: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	152,480	Reported balance After 2026-02-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-02 · Grant · Acquired 152,480 · Balance 152,480 F4: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F3: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

F4: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.

Better Therapeutics, Inc.

Report date December 18, 2023 · Filed December 20, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,031,805	Reported balance After 2023-12-18 transaction · row 1 1 source row Row 1 · 2023-12-18 · Grant · Acquired 3,750 · Balance 1,031,805 F1: The Reporting person was awarded 3,750 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024.
Common StockSEC Table I · non-derivative	IndirectBy Parker Trust	53,333	Reported balance Holding disclosure · report date 2023-12-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 53,333 F2: These shares are owned directly by the Geoffrey M. Parker Rev Trust dtd 1/27/00 (the "Parker Trust"), and indirectly by the Reporting Person and his spouse, Jill G. Parker, as trustees of the Parker Trust.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting person was awarded 3,750 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024.

F2: These shares are owned directly by the Geoffrey M. Parker Rev Trust dtd 1/27/00 (the "Parker Trust"), and indirectly by the Reporting Person and his spouse, Jill G. Parker, as trustees of the Parker Trust.

PERRIGO Co plc

Report date September 11, 2026 · Filed September 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	33,873	Ending reported balance After 2026-09-11 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-11 · Exercise / conversion · Acquired 1,263 · Balance 34,480 Row 2 · 2026-09-11 · Tax withholding · Disposed 607 · Balance 33,873
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-09-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-11 · Exercise / conversion · Disposed 1,263 · Balance 0 F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 September 2026.
Ordinary SharesSEC Table I · non-derivative	IndirectRevocable Trust	25,879	Reported balance Holding disclosure · report date 2026-09-11 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 25,879 F1: Revocable trust in which Geoffrey Parker and Jill Parker are the trustees.
Ordinary SharesSEC Table I · non-derivative	IndirectIRA	17,375	Reported balance Holding disclosure · report date 2026-09-11 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 17,375 F2: Geoffrey M. Parker Roth IRA.

Filing footnotes · ownership attribution and instrument terms

F1: Revocable trust in which Geoffrey Parker and Jill Parker are the trustees.

F2: Geoffrey M. Parker Roth IRA.

F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F4: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 September 2026.

Tricida, Inc.

Report date February 28, 2022 · Filed March 02, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.96 · Expires 2032-02-27	Direct	256,000	Reported balance After 2022-02-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-02-28 · Grant · Acquired 256,000 · Balance 256,000 F1: The option to purchase common stock will vest as follows: (a) 25% of the shares subject to the options shall vest on February 28, 2023, and (b) the remaining 75% vest in 36 equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option to purchase common stock will vest as follows: (a) 25% of the shares subject to the options shall vest on February 28, 2023, and (b) the remaining 75% vest in 36 equal monthly installments thereafter, subject to reporting person's continuous service as of each vesting date.

Viracta Therapeutics, Inc.

Report date May 31, 2017 · Filed June 02, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.96 · Expires 2027-05-31	Direct	25,000	Reported balance After 2017-05-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-05-31 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests over one (1) year in equal monthly installments from the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests over one (1) year in equal monthly installments from the date of grant.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ChemoCentryx, Inc.

Report date October 20, 2022 · Filed October 24, 2022

Section 16 reporting ended · disclosed 2022-10-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-20 transaction · row 1 1 source row Row 1 · 2022-10-20 · Disposition to issuer · Disposed 107,997 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
Common StockSEC Table I · non-derivative	IndirectGeoffrey M Parker & Jill Gofen Parker Trustees of Geoffrey M Parker & Jill G Parker Revocable Trust	Reported balance After 2022-10-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-10-20 · Disposition to issuer · Disposed 21,076 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
Common StockSEC Table I · non-derivative	IndirectBy Delaware Charter Guarantee & Trust Company, Trustee FBO Mr. Geoffrey Monroe Parker IRA	Reported balance After 2022-10-20 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2022-10-20 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised, F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.39	Direct	Reported balance After 2022-10-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-20 · Disposition to issuer · Disposed 8,342 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.06	Direct	Reported balance After 2022-10-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-20 · Disposition to issuer · Disposed 4,504 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $11.60	Direct	Reported balance After 2022-10-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-20 · Disposition to issuer · Disposed 12,287 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.94	Direct	Reported balance After 2022-10-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-20 · Disposition to issuer · Disposed 13,352 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.94	Direct	Reported balance After 2022-10-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-20 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-10-20 · Disposition to issuer · Disposed 15,723 · Balance 0 F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of securities pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 3, 2022, among Amgen Inc. ("Parent"), Carnation Merger Sub, Inc. ("Merger Sub") and ChemoCentryx, Inc. (the "Company"), pursuant to which, on October 20, 2022, Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), each issued and outstanding share of common stock, par value $0.001 per share, of the Company (collectively, the "Shares," and each such share, a "Share") (other than any such Shares (i) held by the Company as treasury stock or owned by Parent or Merger Sub, (ii) held by any subsidiary of the Company or Parent (other than Merger Sub) or (iii) as to which appraisal rights have been properly exercised,

F2: (Continued from Footnote 1) and not withdrawn, in accordance with the Delaware General Corporation Law) was thereupon canceled and converted into the right to receive $52.00 in cash, without interest (the "Merger Consideration"). As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any Shares.

F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each stock option of the Company ("Company Option") held by the Reporting Person that remained outstanding as of immediately prior to the Effective Time vested in full and was canceled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the number of Shares underlying such Company Option immediately prior to the Effective Time by (y) the amount, if any, by which the Merger Consideration exceeded the exercise price of such Company Option.

F4: At the Effective Time, each restricted stock unit of the Company held by the Reporting Person that was outstanding immediately prior to the Effective Time and that was (A) granted prior to August 3, 2022 or granted after August 3, 2022 and specified in the disclosure schedules delivered by the Company to Parent in connection with the Merger Agreement and/or (B) granted to a non-employee member of the Board became fully vested and was cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes and without interest, equal to (x) the total number of Shares underlying such restricted stock unit multiplied by (y) $52.00. The restricted stock units did not have an expiration date.

GENOMIC HEALTH INC

Report date November 08, 2019 · Filed November 14, 2019

Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-11-08 transaction · row 1 1 source row Row 1 · 2019-11-08 · Grant · Disposed 955 · Balance 0 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.07 · Expires 2026-06-21	Direct	Reported balance After 2019-11-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $335,468 and 5,494 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the terms of the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.53 · Expires 2027-06-16	Direct	Reported balance After 2019-11-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.72 · Expires 2028-06-07	Direct	Reported balance After 2019-11-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.41 · Expires 2029-06-14	Direct	Reported balance After 2019-11-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-08 · Disposition to issuer · Disposed 6,583 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.

F2: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $335,468 and 5,494 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the terms of the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.

F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.

F5: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 11, 2026 Filed Sep 15, 2026 20:19 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	1,263	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-26-000151 · wk-form4_1789503553.xml · derivative · entry 5 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,263 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 September 2026. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 September 2026. Read SEC document
September 11, 2026 Filed Sep 15, 2026 20:19 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	607	$13.66	$8,291.62	Disclosure SEC source: 0001585364-26-000151 · wk-form4_1789503553.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,873 Read SEC document
September 11, 2026 Filed Sep 15, 2026 20:19 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	1,263	$13.66	$17,252.58	Disclosure SEC source: 0001585364-26-000151 · wk-form4_1789503553.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 12, 2026 Filed Jun 16, 2026 20:54 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	976	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-26-000097 · wk-form4_1781643242.xml · derivative · entry 6 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 976 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F5 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 13 June 2026. Read SEC document
June 12, 2026 Filed Jun 16, 2026 20:54 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	844	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-26-000097 · wk-form4_1781643242.xml · derivative · entry 5 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 844 Underlying: Ordinary Shares · 844 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on June 12 2027. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on June 12 2027. Read SEC document
June 12, 2026 Filed Jun 16, 2026 20:54 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	469	$10.99	$5,154.31	Disclosure SEC source: 0001585364-26-000097 · wk-form4_1781643242.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,217 Read SEC document
June 12, 2026 Filed Jun 16, 2026 20:54 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	976	$10.99	$10,726.24	Disclosure SEC source: 0001585364-26-000097 · wk-form4_1781643242.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2026 Filed May 15, 2026 20:59 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	7,305	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-26-000075 · wk-form4_1778878789.xml · derivative · entry 6 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,305 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F5 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026. Read SEC document
May 14, 2026 Filed May 15, 2026 20:59 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	3,507	$10.84	$38,015.88	Disclosure SEC source: 0001585364-26-000075 · wk-form4_1778878789.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,710 Read SEC document
May 14, 2026 Filed May 15, 2026 20:59 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	7,305	$10.84	$79,186.20	Disclosure SEC source: 0001585364-26-000075 · wk-form4_1778878789.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,217 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 13, 2026 Filed May 15, 2026 20:59 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	16,681	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-26-000075 · wk-form4_1778878789.xml · derivative · entry 5 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,681 Underlying: Ordinary Shares · 16,681 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on May 13 2027. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on May 13 2027. Read SEC document
March 13, 2026 Filed Mar 17, 2026 16:49 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	3,024	Not disclosed	Not disclosed	Disclosure SEC source: 0001491874-26-000002 · wk-form4_1773766135.xml · derivative · entry 4 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,024 Underlying: Ordinary Shares · 3,024 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on March 13 2027. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on March 13 2027. Read SEC document
February 02, 2026 Filed Feb 4, 2026 22:16 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantRestricted Stock Unit · Derivative	152,480	$0.00	$0.00	Disclosure SEC source: 0001737287-26-000007 · wk-form4_1770243376.xml · derivative · entry 3 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,480 Underlying: Common Stock · 152,480 shares Expires not disclosed F4 · derivative.exercise_price: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. F4 · derivative.exercise_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. F4 · derivative.expiration_date: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date. Read SEC document
February 02, 2026 Filed Feb 4, 2026 22:16 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to buy) · Derivative	539,072	$0.00 Strike: $1.87	$0.00	Disclosure SEC source: 0001737287-26-000007 · wk-form4_1770243376.xml · derivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 539,072 Underlying: Common Stock · 539,072 shares Expires 2036-02-02 F3 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document
February 02, 2026 Filed Feb 4, 2026 22:16 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	SaleCommon Stock	24,001	$1.76	$42,241.76	Disclosure SEC source: 0001737287-26-000007 · wk-form4_1770243376.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,252,795 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
December 12, 2025 Filed Dec 16, 2025 15:44 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	2,140	Not disclosed	Not disclosed	Disclosure SEC source: 0001491874-25-000009 · wk-form4_1765899872.xml · derivative · entry 4 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,140 Underlying: Ordinary Shares · 2,140 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 December 2026. Read SEC document
November 12, 2025 Filed Nov 14, 2025 15:45 UTC	PERRIGO Co plc PRGO · Entity 4516	PurchaseOrdinary Shares	7,500	$14.18	$106,350.00	Disclosure SEC source: 0001491874-25-000007 · wk-form4_1763135134.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · IRA Disclosed balance after: 17,375 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.16 to $14.20, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4 F2 · ownership.nature: Geoffrey M. Parker Roth IRA. Read SEC document
October 21, 2025 Filed Oct 23, 2025 22:20 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	SaleCommon Stock	36,744	$1.26	$46,168.84	Disclosure SEC source: 0001737287-25-000091 · wk-form4_1761258041.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,276,796 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Pursuant to an employee stock purchase program, includes 6,000 shares of the Issuer's common stock acquired by the reporting person on March 14, 2025 and 6,000 shares of the Issuer's common stock acquired by the reporting person on September 15,2025. Read SEC document
September 12, 2025 Filed Sep 16, 2025 16:16 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	1,263	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-25-000146 · wk-form4_1758039410.xml · derivative · entry 4 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,263 Underlying: Ordinary Shares · 1,263 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 September 2026. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 12 September 2026. Read SEC document
August 18, 2025 Filed Aug 19, 2025 14:56 UTC	PERRIGO Co plc PRGO · Entity 4516	PurchaseOrdinary Shares	4,375	$22.97	$100,497.25	Disclosure SEC source: 0001585364-25-000128 · wk-form4_1755615389.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,287 Read SEC document
August 18, 2025 Filed Aug 20, 2025 12:11 UTC Amendment	PERRIGO Co plc PRGO · Entity 4516	PurchaseOrdinary Shares	4,375	$22.97	$100,497.25	Disclosure SEC source: 0001585364-25-000130 · wk-form4a_1755691860.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · IRA Disclosed balance after: 9,875 F1 · ownership.nature: Geoffrey M. Parker Roth IRA. F2 · ownership.nature: This Form 4/A is being filed to correct the manner in which the Reporting Person purchased shares of Perrigo Company plc. The original Form 4, filed on August 19, 2025 (the "Original Form 4") reported the purchase of 4,375 shares by Mr. Parker directly, where such shares were in fact acquired indirectly by the Geoffrey M. Parker Roth IRA, as reflected in this Form 4/A. Other than as described in this footnote, there are no other changes from the Original Form 4. Read SEC document
June 13, 2025 Filed Jun 17, 2025 18:18 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	976	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-25-000107 · wk-form4_1750184326.xml · derivative · entry 4 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 976 Underlying: Ordinary Shares · 976 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 13 June 2026. Read SEC document
May 14, 2025 Filed May 16, 2025 15:52 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	9,904	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-25-000074 · wk-form4_1747410747.xml · derivative · entry 6 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F5 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. F5 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. Read SEC document
May 14, 2025 Filed May 16, 2025 15:52 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	7,305	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-25-000074 · wk-form4_1747410747.xml · derivative · entry 5 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,305 Underlying: Ordinary Shares · 7,305 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026. Read SEC document
May 14, 2025 Filed May 16, 2025 15:52 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	4,754	$26.01	$123,651.54	Disclosure SEC source: 0001585364-25-000074 · wk-form4_1747410747.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,912 Read SEC document
May 14, 2025 Filed May 16, 2025 15:52 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	9,904	$26.01	$257,603.04	Disclosure SEC source: 0001585364-25-000074 · wk-form4_1747410747.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 12, 2025 Filed May 14, 2025 18:06 UTC	PERRIGO Co plc PRGO · Entity 4516	PurchaseOrdinary Shares	3,500	$27.10	$94,850.00	Disclosure SEC source: 0001585364-25-000058 · wk-form4_1747245994.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,762 Read SEC document
February 03, 2025 Filed Feb 5, 2025 21:15 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	SaleCommon Stock	4,361	$1.73	$7,544.53	Disclosure SEC source: 0001737287-25-000019 · wk-form4_1738790139.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,301,540 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document
January 24, 2025 Filed Jan 29, 2025 01:15 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to buy) · Derivative	614,844	$0.00 Strike: $1.94	$0.00	Disclosure SEC source: 0001737287-25-000008 · wk-form4_1738113304.xml · derivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 614,844 Underlying: Common Stock · 614,844 shares Expires 2035-01-24 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document
January 24, 2025 Filed Jan 29, 2025 01:15 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantCommon Stock	173,913	$0.00	$0.00	Disclosure SEC source: 0001737287-25-000008 · wk-form4_1738113304.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,305,901 Read SEC document
October 21, 2024 Filed Oct 23, 2024 20:21 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	Tax withholdingCommon Stock	36,404	$2.84	$103,387.36	Disclosure SEC source: 0001737287-24-000065 · wk-form4_1729714884.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,131,988 F1 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.82 to $2.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F3 · balance_after: Includes 3,974 shares of the Issuer's common stock acquired by the reporting person on September 15, 2024 pursuant to an employee stock purchase program. Read SEC document
May 16, 2024 Filed May 20, 2024 22:02 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantCommon Stock	344,828	$2.90	$1,000,001.20	Disclosure SEC source: 0001593968-24-000715 · primary_01.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,164,418 F1 · shares: These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the "Issuer") in a registered direct offering. Read SEC document
May 15, 2024 Filed May 16, 2024 23:28 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	8,764	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-24-000090 · wk-form4_1715902105.xml · derivative · entry 4 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 8,764 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. Read SEC document
May 15, 2024 Filed May 16, 2024 23:28 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	4,207	$30.22	$127,135.54	Disclosure SEC source: 0001585364-24-000090 · wk-form4_1715902105.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,262 Read SEC document
May 15, 2024 Filed May 16, 2024 23:28 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	8,764	$30.22	$264,848.08	Disclosure SEC source: 0001585364-24-000090 · wk-form4_1715902105.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2024 Filed May 16, 2024 23:28 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	9,904	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-24-000090 · wk-form4_1715902105.xml · derivative · entry 3 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,904 Underlying: Ordinary Shares · 9,904 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025. Read SEC document
January 30, 2024 Filed Mar 7, 2024 02:52 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	PurchaseCommon Stock	190	$3.60	$683.05	Disclosure SEC source: 0001593968-24-000449 · primary_01.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 819,590 F1 · shares: Mr. Parker was notified by his broker on March 4, 2024 that these shares were purchased in an account held by the Geoffrey M. Parker and Jill G. Parker Rev. Trust dated January 27, 2000 for which Mr. Parker does not have discretion. This account is intended to closely track the performance of the Russell 2000 and is frequently rebalanced by an algorithm designed by the broker which led to the purchase of these shares. Restrictions have been now placed on all such accounts held by the Trust to avoid such purchases of the Issuer stock in the future. Read SEC document
January 25, 2024 Filed Jan 31, 2024 22:47 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to buy) · Derivative	103,939	$0.00 Strike: $3.20	$0.00	Disclosure SEC source: 0001593968-24-000195 · primary_01.xml · derivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,939 Underlying: Common Stock · 103,939 shares Expires 2034-01-25 F1 · derivative.exercise_date: 1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter. Read SEC document
January 25, 2024 Filed Jan 31, 2024 22:47 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantCommon Stock	29,400	$0.00	$0.00	Disclosure SEC source: 0001593968-24-000195 · primary_01.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 819,400 Read SEC document
December 18, 2023 Filed Dec 20, 2023 22:22 UTC	Better Therapeutics, Inc. BTTX · Entity 94385	GrantCommon Stock	3,750	$0.00	$0.00	Disclosure SEC source: 0000950170-23-071958 · ownership.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,031,805 F1 · shares: The Reporting person was awarded 3,750 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest on June 1, 2024. Read SEC document
October 16, 2023 Filed Oct 17, 2023 21:02 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to Buy) · Derivative	950,000	$0.00 Strike: $3.24	$0.00	Disclosure SEC source: 0001593968-23-001369 · primary_01.xml · derivative · entry 3 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 950,000 Underlying: Common Stock · 950,000 shares Expires 2033-10-16 F2 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on October 16, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document
October 16, 2023 Filed Oct 17, 2023 21:02 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantCommon Stock	390,000	$0.00	$0.00	Disclosure SEC source: 0001593968-23-001369 · primary_01.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 790,000 F1 · acquired: Constitutes Performance Restricted Stock Units ("PRSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each PRSU upon vesting, 50% shall vest in the event the Company achieves a 30-day weighted average share price of $18 on or before March 22, 2026 and 50% shall vest upon the first marketing approval of a Company product by the US FDA on or before March 22, 2028. Read SEC document
October 16, 2023 Filed Oct 17, 2023 21:02 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantCommon Stock	400,000	$0.00	$0.00	Disclosure SEC source: 0001593968-23-001369 · primary_01.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Read SEC document
July 27, 2023 Filed Jul 31, 2023 11:58 UTC	Better Therapeutics, Inc. BTTX · Entity 94385	PurchaseCommon Stock	685,025	$0.73	$499,999.75	Disclosure SEC source: 0000950170-23-035679 · ownership.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,028,055 F1 · kind: On July 25, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the "PIPE Investors") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.7299 per share. F2 · kind: As one of the PIPE Investors, the Reporting Person acquired 685,025 shares of Issuer common stock on July 27, 2023 for $0.7299 per share. Read SEC document
June 13, 2023 Filed Jun 14, 2023 14:54 UTC	PERRIGO Co plc PRGO · Entity 4516	PurchaseOrdinary Shares	10,000	$33.06	$330,637.00	Disclosure SEC source: 0001585364-23-000106 · wf-form4_168675447611252.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Revocable Trust Disclosed balance after: 25,879 F1 · ownership.nature: Revocable trust in which Geoffrey Parker and Jill Parker are the trustees. Read SEC document
June 07, 2023 Filed Jun 9, 2023 22:55 UTC	Better Therapeutics, Inc. BTTX · Entity 94385	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $0.77	$0.00	Disclosure SEC source: 0000950170-23-027334 · ownership.xml · derivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-06 F1 · derivative.exercise_date: The stock option vests in full on the earlier of the first anniversary of the grant date and the Issuer's next annual meeting of stockholders, provided that the Reporting Person continues to serve as a director of the Issuer on such vesting date. The stock option was granted on June 7, 2023. Read SEC document
May 17, 2023 Filed May 19, 2023 18:38 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	7,778	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-23-000096 · wf-form4_168452149168169.xml · derivative · entry 5 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2022. F3 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 17 May 2023. Read SEC document
May 17, 2023 Filed May 19, 2023 18:38 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	3,734	$32.86	$122,699.24	Disclosure SEC source: 0001585364-23-000096 · wf-form4_168452149168169.xml · nonDerivative · entry 2 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,705 Read SEC document
May 17, 2023 Filed May 19, 2023 18:38 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	7,778	$32.86	$255,585.08	Disclosure SEC source: 0001585364-23-000096 · wf-form4_168452149168169.xml · nonDerivative · entry 1 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on 17 May 2022. Read SEC document
May 15, 2023 Filed May 17, 2023 19:40 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	8,764	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-23-000075 · wf-form4_168435244294643.xml · derivative · entry 4 Parker Geoffrey M. · CIK 0001491874 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,764 Underlying: Ordinary Shares · 8,764 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 15 May 2024. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.